# A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma

> **NCT06700395** · PHASE1 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 136 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** TQB2029 injection

## Key facts

- **NCT ID:** NCT06700395
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-28
- **Primary completion:** 2026-03
- **Final completion:** 2028-03
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06700395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06700395, "A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT06700395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*